Speaker illustration

Miss Anouk Achten

Cardiovascular Research Institute Maastricht (CARIM), Maastricht (Netherlands (The))

Peroxiredoxin-4 and beta-hydroxybutyrate after SGLT2 inhibitor treatment in heart failure with preserved ejection fraction

Event: Heart Failure 2025

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Diagnosis and prognosis of HFpEF

Thumbnail

Sex-specific performance of HFpEF diagnostic algorithms across two independent cohorts

Event: Heart Failure 2025

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Exploring physiological and regional variations in HFpEF

Thumbnail

Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction

Event: Heart Failure 2024

Topic: Systolic Ventricular Dysfunction

Session: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment

Thumbnail

True prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort

Event: Heart Failure 2024

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic heart failure - pathophysiology and mechanisms 10

Thumbnail

A ventricular conduction delay phenotype and its outcome in heart failure with preserved ejection fraction

Event: Heart Failure 2023

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Heart failure with preserved ejection fraction (HFpEF) 3

Thumbnail

Changes in diagnostic trajectory of cardiac amyloidosis over 6 years: role of improving awareness

Event: Heart Failure 2023

Topic: Epidemiology, Prognosis, Outcome

Session: ePosters in chronic heart failure - epidemiology, prognosis, outcome 3

Thumbnail